Brain Penetrant LRRK2 Inhibitor.

Activating mutations in leucine-rich repeat kinase 2 (LRRK2) are present in a subset of Parkinson's disease (PD) patients and may represent an attractive therapeutic target. Here we report a 2-anilino-4-methylamino-5-chloropyrimidine, HG-10-102-01(4) is a potent and selective inhibitor of wild-type LRRK2 and the G2019S mutant. Compound 4 substantially inhibits Ser910 and Ser935 phosphorylation of both wild-type LRRK2 and G2019S mutant at a concentration of 0.1-0.3 µM in cells and is the first compound reported to be capable of inhibiting Ser910 and Ser935 phosphorylation in mouse brain following intraperitoneal delivery of doses as low as 50 mg/kg.

[1]  C. Tanner,et al.  Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 , 2007, Neurology.

[2]  M. Cookson,et al.  Role of LRRK2 kinase dysfunction in Parkinson disease , 2011, Expert Reviews in Molecular Medicine.

[3]  G. Drewes,et al.  Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. , 2011, ACS chemical biology.

[4]  E. Tolosa,et al.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.

[5]  Mindy I. Davis,et al.  Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[6]  T. Yeh,et al.  (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD , 2012, Cell Death and Differentiation.

[7]  V. Baekelandt,et al.  On the Road to Leucine-Rich Repeat Kinase 2 Signalling: Evidence from Cellular and in vivo Studies , 2011, Neurosignals.

[8]  Y. Liu,et al.  Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2 , 2011, PloS one.

[9]  M. Cookson,et al.  Leucine-rich repeat kinase 2 mutations and Parkinson’s disease: three questions , 2009, ASN neuro.

[10]  P. Aebischer,et al.  A Rat Model of Progressive Nigral Neurodegeneration Induced by the Parkinson's Disease-Associated G2019S Mutation in LRRK2 , 2011, The Journal of Neuroscience.

[11]  Andrea Lombardi Borgia,et al.  Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. , 2010, Biochemistry.

[12]  Y. Durocher,et al.  High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. , 2002, Nucleic acids research.

[13]  Jason Drummond,et al.  Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. , 2012, Journal of medicinal chemistry.

[14]  P. Griffin,et al.  Potent, Selective and Cell Penetrant Inhibitors of SF-1 by Functional Ultra-High-Throughput Screening , 2008, Molecular Pharmacology.

[15]  R. Nichols,et al.  LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. , 2007, The Biochemical journal.

[16]  C. Ross,et al.  Kinase activity of mutant LRRK2 mediates neuronal toxicity , 2006, Nature Neuroscience.

[17]  Xianming Deng,et al.  Characterization of TAE684 as a potent LRRK2 kinase inhibitor. , 2012, Bioorganic & medicinal chemistry letters.

[18]  N. Gray,et al.  Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2 , 2011, Nature chemical biology.

[19]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[20]  T. Dawson,et al.  Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. , 2011, Human molecular genetics.

[21]  T. Dawson,et al.  Inhibitors of LRRK 2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson ’ s disease models , 2011 .

[22]  Shu G. Chen,et al.  Leucine‐rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease , 2009, Journal of neuroscience research.

[23]  M. Farrer,et al.  LRRK2 and Parkinson disease. , 2010, Archives of neurology.

[24]  T. Dawson,et al.  Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. , 2012, Trends in pharmacological sciences.